arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Lucid Diagnostics Inc.

LUCD
$0.39 ▼ -0.06 (-13.43%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
26 Visible periods
28 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Lucid Diagnostics Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $71.4M
Dividend Yield —
Revenue Growth 26.7% ↘
Op. Margin —
ROIC -117.2% ↗
FCF / Share $-0.06 ↗
Trailing P/E —
Price / Book 6.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.47M
↑ +26.7% —
Net Income Profit after all expenses
$-11.69M
↓ -163.3% —
FCF / Share Free cash flow per share
$-0.06
↑ +29.7% —
Long-Term Debt Long-term obligations
$24.28M
↑ +126.0% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -453.9% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.80x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 26 quarters